A novel US manufacturing process from Vulpes will offer farmers a secure, price competitive, domestic supply of Ethalfluralin for the first time in recent history.
For years, American farmers have faced significant supply-chain risk for Ethalfluralin. Until now, the US market has relied on a single European manufacturer supplying a single domestic distributor, creating a fragile system vulnerable to global disruptions.
Today, Vulpes, in partnership with Actylis, is proud to announce that the US The Environmental Protection Agency (EPA) has approved our technical registration for Ethalfluralin. This will now begin the cost-competitive US production beginning in time for the 2026 growing season.
A New Domestic Manufacturing Process
Vulpes has developed an entirely new process that allows Ethalfluralin to be produced in the United States. Our innovation proves that domestic manufacturing capabilities surpass global producers on cost without compromising quality or reliability.
This advancement eliminates the forced choice farmers have faced for years between “made in the US” and “affordable.” With Vulpes, now both are available.
Major benefits to the US agriculture
Our Ethalfluralin production brings major benefits to the US agricultural sector:
- Stable supply, no longer tied to a single foreign producer
- Reduced exposure to global disruptions or shocks
- Reliable domestic sourcing, reinforcing national agricultural resilience
- Competitive pricing, made possible through our innovative chemistry and optimized efficiency
Through Actylis’s nationwide distribution network, American farmers will have broad access to a secure domestic alternative starting in 2026.
Moving Forward
The approval of the Ethalfluralin technical registration is more than a regulatory milestone—it demonstrates that American fine-chemical manufacturing can lead again. Vulpes will continue investing in innovation and operational excellence to fortify domestic supply chains and deliver competitive US-made solutions to farmers across the country.